Table 2.
Patients’ clinical data, n (%)
|
|
Control group
|
Experimental group
|
χ2/Z score |
P
value
|
| Cancer diagnosis | 4.693 | 0.584 | ||
| Breast cancer | 6 (14.60) | 4 (9.10) | ||
| Lung cancer | 7 (17.10) | 6 (13.60) | ||
| Gastrointestinal cancer | 7 (17.10) | 12 (27.30) | ||
| Nasopharyngeal cancer | 2 (4.90) | 4 (9.10) | ||
| Gynecological cancer | 14 (34.10) | 16 (36.40) | ||
| Pancreatic cancer | 2 (4.90) | 0 (0.00) | ||
| Others | 3 (7.30) | 2 (4.50) | ||
| Metastasis | 0.848 | 0.357 | ||
| Yes | 16 (39.00) | 13 (29.50) | ||
| No | 25 (61.00) | 31 (70.50) | ||
| Clinical manifestation status | –0.0281 | 0.978 | ||
| Grade 0 | 16 (40.00) | 9 (20.50) | ||
| Grade 1 | 7 (17.50) | 23 (52.30) | ||
| Grade 2 | 9 (22.50) | 7 (15.90) | ||
| Grade 3 | 4 (10.00) | 5 (11.40) | ||
| Grade 4 | 4 (10.00) | 0 (0.00) | ||
| Stratification | 5.320 | 0.150 | ||
| Asymptomatic, stable, anti-cancer | 6 (15.40) | 5 (11.40) | ||
| Asymptomatic, stable, not anti-cancer | 2 (5.10) | 1 (2.30) | ||
| Symptomatic, anti-cancer remission | 24 (61.50) | 36 (81.80) | ||
| Symptomatic, symptom control | 7 (17.90) | 2 (4.50) | ||
| Treatment | 16.467 | 0.110 | ||
| Palliative care | 7 (17.10) | 0 (0.00) | ||
| Radiotherapy | 0 (0.00) | 5 (11.40) | ||
| Chemotherapy | 28 (68.30) | 31 (70.50) | ||
| Hormone Therapy | 0 (0.00) | 2 (4.50) | ||
| Chemoradiotherapy | 6 (14.60) | 4 (9.10) | ||
| Others | 0 (0.00) | 2 (4.60) | ||
1
The Mann-Whitney U test.